Asana BioSciences Announces Dosing of First Patient in Phase 1 Trial of ASN004, a Novel 5T4-Antibody-Drug-Conjugate
Retrieved on:
Freitag, April 8, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Janus, DAR, Principal, Motor neuron, Itch, Cough, Neck, Pharmacokinetics, ADC, Clinical research, Cancer, Monomethyl auristatin F, 5T4, Doctor of Philosophy, Head, Asana, Program, Neoplasm, Janus kinase, Pain, LLC, Safety, JAK3, JAK1, TYK2, ATP, SYK, PI3K, Neuron, JAK, Kinase, Atopic dermatitis, JAK2, Patient, Large-cell lung carcinoma, Respiratory disease, Vaccine, Pharmaceutical industry
ASN004 incorporates a novel single-chain Fv-Fc antibody linked to a clinically validated Auristatin F hydroxypropylamide cytotoxic payload, and drug to antibody ratio (DAR) of approximately 10-12.
Key Points:
- ASN004 incorporates a novel single-chain Fv-Fc antibody linked to a clinically validated Auristatin F hydroxypropylamide cytotoxic payload, and drug to antibody ratio (DAR) of approximately 10-12.
- In preclinical cancer models, a single dose of ASN004 achieved complete and durable tumor regression leading to tumor-free survivors.
- Asana is focused on discovery and development of novel targeted investigational medicines in immunology/inflammation and oncology.
- In a Phase 1b study in atopic dermatitis patients, topical application of ASN008 showed rapid onset of pruritus relief (NCT03798561).